Kleo Pharmaceuticals and Green cross LabCell are developing combination therapy of Antibody Recruiting Molecule and (ARM™) and allogeneic natural killer cells, for the treatment of COVID-2019 infections. Under the collaboration, Kleo will leverage its proprietary ARM platform whereas green cross Labcell willlaverage its allogeneic, or “off-the-shelf” natural killer cell therapies platform. Antibody recruiting molecule (ARM™) are bispecific molecules, designed to recruit the endogenous antibodies on virus particles, targeting them for destruction by engaging natural killer (NK) cells. It works as a bridge by enabling coating of antibodies to the cell and leading to the destruction of the virus particle through innate antibody-mediated immune mechanisms. Early research is underway in South Korea and the US.
ARMs are bifunctional molecules composed of two active terminus connected by a linker. One of the terminus binds tightly to a target molecule on SARS-Cov-2 virus. The other universal antibody binding terminus (uABT) binds to all endogenous antibodies independent of their antigen binding specificity. As a result, the target virus particle is "opsonised" by antibodies which then bring the allogeneic natural killer cells to eliminate the virus through various antibody-dependent destruction mechanisms. Moreover, the ARMs can produce a long-term vaccination effect by activating and expanding immune memory cells.
In March 2020, Kleo Pharmaceuticals entered into a research collaboration with Green Cross LabCell to discover and develop therapies for the treatment of COVID-2019 infections. Under the collaboration, Kleo will leverage its ARM technology platform to develop fully synthetic bifunctional molecules and Green Cross LabCell will leverage its allogeneic natural killer cell therapy platform, to develop a combination therapy for COVID-2019 infections.